Sugi Predict

Sugi Predict / Compounds / SCHEMBL258964

SCHEMBL258964

SCHEMBL258964

Oc1cccc(-c2nc(N3CCOCC3)c3nccnc3n2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 20/20 0.74
▸ PIK3CG P48736 11/20 0.74
▸ MTOR P42345 10/20 0.74
▸ PIK3CD O00329 8/20 0.74
▸ PIK3CB P42338 4/20 0.60
▸ PIK3C2B O00750 3/20 0.60
▸ PIK3C2A O00443 1/20 0.60
▸ CHUK O15111 1/20 0.60
▸ DAPK3 O43293 1/20 0.60
▸ PIK3C2G O75747 1/20 0.60
▸ RAF1 P04049 1/20 0.60
▸ BRAF P15056 1/20 0.60
▸ CSNK2A2 P19784 1/20 0.60
▸ JAK1 P23458 1/20 0.60
▸ PIK3R1 P27986 1/20 0.60
▸ TYK2 P29597 1/20 0.60
▸ FLT3 P36888 1/20 0.60
▸ CLK1 P49759 1/20 0.60
▸ CLK2 P49760 1/20 0.60
▸ CLK3 P49761 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL258574 0.85 PIK3CA (1.00) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL1308205 0.81 PIK3CA (0.66) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL1308864 0.80 PIK3CA (0.68) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL4443377 0.80 PIK3CA (0.70) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL25276720 0.78 PIK3CA (0.86) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL16912793 0.78 PIK3CA (0.72) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL258469 0.77 PIK3CA (0.65) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL16912825 0.76 PIK3CA (0.69) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL16912807 0.76 PIK3CA (0.69) PIK3CAPIK3CGMTORPIK3CDPIK3CB
SCHEMBL16920289 0.76 PIK3CA (0.69) PIK3CAPIK3CGMTORPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 — — EP claimed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US claimed
US-6838457-B2 Fused heteroaryl derivatives YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-04 — — US claimed
US-20040009978-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2004-01-15 — — US claimed
US-20030236271-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2003-12-25 — — US claimed
EP-1277738-A1 CONDENSED HETEROARYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 — — EP claimed
US-20020151544-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2002-10-17 — — US claimed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 — — US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 — — EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 — — US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
WO-2004017950-A2 PHOSPHADIDYLINOSITOL 3,5-BIPHOSPHATE INHIBITORS AS ANTI-VIRAL AGENTS PIRAMED LIMITED (GB) 2004-03-04 — — WO disclosed
US-20040009978-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2004-01-15 — — US disclosed
US-20030236271-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2003-12-25 — — US disclosed
US-6608056-B1 Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) 2003-08-19 — — US disclosed
US-6608053-B2 Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 — — US disclosed
EP-1277738-A1 CONDENSED HETEROARYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 — — EP disclosed
US-20020151544-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236271-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885
US-20040009978-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885
US-20020151544-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.